Saturday 17 October 2026
Export CADL’s income statement to Excel — free account
Candel Therapeutics, Inc.
CADL Healthcare Biotechnology
Candel Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $125,000.00. In the quarter to June 2026, EPS fell 477.8%, free cash flow fell 93.4% and total debt rose 525.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.19
0.72
−8.08%
Follow CADL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (81.84%) | (51.17%) | (64.58%) | (70.17%) |
+8 more TTM periods Free account |
|
| (56.37%) | (36.55%) | (32.91%) | (39.54%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(45.76%) | (28.23%) | (33.48%) | (28.25%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.77) | (0.79) | (0.73) | (0.61) | |
Free Cash Flow |
(57.29) | (48.96) | (38.87) | (33.71) | |
Capital Expenditures |
(1.27) | (1.23) | (0.56) | (0.15) | |
| Other line items | |||||
Cash ROIC |
(15.26%) | (12.87%) | (17.77%) | (19.57%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(15.26) | (16.71) | (22.78) | (37.20) | |
Operating CF/Net income |
0.63 | 0.88 | 1.00 | 1.47 | |
Depreciation/Fixed assets |
0.34 | 0.36 | 0.51 | 0.68 | |
Capex/Depreciation |
(1.87) | (1.64) | (0.66) | (0.17) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.76) | (0.77) | (0.72) | (0.61) | |
Capex per Share |
(0.02) | (0.02) | (0.01) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates